地拉罗司治疗铁质积聚疗效好吗？

(Enrig) Is it effective to treat iron accumulation? Deferasirox (Enrigen) was developed by Novartis, and Indian cipla pharmaceutical company also has a generic version of Deferasirox (Enrigen). Deferasirox (Enrige) is currently the only oral iron chelator. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions.

To analyze the clinical efficacy and adverse reactions of the new iron chelator deferasirox (Enrige) in the treatment of secondary iron overload in myelodysplastic syndrome (MDS). This study retrospectively analyzed the clinical data of patients with secondary iron overload in MDS who were treated with the new iron chelator deferasirox (Enrige) at the People's Liberation Army General Hospital from January 2012 to April 2014, and observed serum ferritin (SF), red blood cell transfusion volume, hemoglobin and adverse drug reactions before and after treatment.

Results: A total of 8 MDS patients with secondary iron overload were taking deferasirox (Enrige), including 7 males and 1 female, with a median age of 52 (38-71) years old. After 3 months of treatment, the efficacy was evaluated as complete response (CR) in 3 cases, minimal reaction (MiR) in 3 cases, and stable iron overload (SIL) in 2 cases. The overall response rate was 75.0% (6/8), and the median red blood cell transfusion volume was 2 (1-3) u/month. After 1 year of treatment, the efficacy was evaluated as CR in 5 cases, MiR in 2 cases, and SIL in 1 case. The overall response rate was 87.5% (7/8).

Compared with before treatment, the patient's SF was significantly reduced [(871.0±584.2) vs (2164.9±1233.6) ng/ml] and hemoglobin was significantly increased [(101.5±34.59) vs (65.37±21.35) g/L] after 1 year of treatment, and the differences were statistically significant (P<0.05). After 1 year, 5 patients were weaned from blood transfusion, and the median red blood cell transfusion volumes of the remaining 3 patients were 0.5 u/month, 1.5 u/month, and 2.0 u/month respectively. After 1 year of treatment, only one patient died. There were 3 cases of nausea and vomiting and 1 case of diarrhea after taking the medicine. The results show that (Enrig) ​​is very effective in treating iron accumulation.

Recommended related articles: